RT Journal Article
SR Electronic
T1 Pre-clinical Immunogenicity and Anti-tumour Efficacy of a Deleted Recombinant Human Papillomavirus Type 16 E7 Protein
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2265
OP 2276
VO 24
IS 4
A1 SOPHIE HALLEZ
A1 JEAN-MARC BRULET
A1 CAROLINE VANDOOREN
A1 FRÉDÉRIC MAUDOUX
A1 SÉVERINE THOMAS
A1 MICHEL HEINDERICKX
A1 ALEX BOLLEN
A1 RUDDY WATTIEZ
A1 ALAIN JACQUET
YR 2004
UL http://ar.iiarjournals.org/content/24/4/2265.abstract
AB Background: Current vaccination strategies against Human papillomavirus (HPV)-induced ano-genital cancers mostly target E7 from HPV16. However, the oncogenic nature of E7 raises potential human safety issues. Although the modifications abrogating the E7 transforming potential have been well characterized, their effect on E7 immunogenicity has been poorly studied. In this study, we evaluated the vaccine potential of an HPV16 E7 protein deleted from the entire pRb-binding motif. Materials and Methods: Purified recombinant deleted (E7Δ21-26) and wild-type (His6-E7 and E7WT) E7 proteins were studied in pre-clinical mice models. Results: In C57BL/6 mice, E7Δ21-26 formulated with the Quil A adjuvant generated systemic E7-specific cytotoxic T-cell and antibody responses similar to those induced following His6-E7/Quil A and E7WT/Quil A vaccinations. E7Δ21-26/Quil A injections efficiently protected animals from challenge with the HPV16-expressing tumours, C3 and TC-1. Moreover, therapeutic vaccination with adjuvant-modified E7 suppressed or significantly decreased C3 tumour outgrowth. Conclusion: E7Δ21-26 could represent a safe and efficient vaccine candidate against E7-containing tumour cells. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved